G protein-coupled receptors

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

Retrieved on: 
Thursday, August 6, 2020
Hormones, Drugs, Peptide hormones, Vasoactivity, Vasoactive intestinal peptide, Peptide, Branches of biology, G protein-coupled receptors

The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure.

Key Points: 
  • The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure.
  • The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before September 1, 2020.
  • Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970.
  • Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses.

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

Retrieved on: 
Thursday, August 6, 2020
Hormones, Drugs, Peptide hormones, Vasoactivity, Vasoactive intestinal peptide, Peptide, Branches of biology, G protein-coupled receptors

The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure.

Key Points: 
  • The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure.
  • The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before September 1, 2020.
  • Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970.
  • Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses.

Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference

Retrieved on: 
Tuesday, August 4, 2020
Drugs, Branches of biology, Hormones, Antidiuretics, Peptides, Neuropeptides, Orgasm, G protein-coupled receptors, Oxytocin, Atosiban, Nasal administration

In June 2020 Tonix acquired the assets of Trigemina, including certain rights to the data described in the presentation.

Key Points: 
  • In June 2020 Tonix acquired the assets of Trigemina, including certain rights to the data described in the presentation.
  • Intranasal oxytocin was also shown to attenuate post-traumatic brain injury depressive and anxiety behaviors in the same animal model.
  • These effects were blocked by the oxytocin receptor antagonist, Atosiban, indicating the effects of intranasal oxytocin were mediated by oxytocin receptors.
  • The Company expects results from an unblinded interim analysis in September 2020 and topline data in the fourth quarter of 2020.

Global Market Landscape for the Endocannabinoid System Targeted Therapeutics Market 2020 - Development Pipeline for Drugs Targeting Endocannabinoid System

Retrieved on: 
Friday, July 31, 2020
Neurochemistry, Cannabinoids, G protein-coupled receptors, Endocannabinoid system

DUBLIN, July 31, 2020 /PRNewswire/ -- The "Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 31, 2020 /PRNewswire/ -- The "Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • In addition, nearly 20 million Americans are estimated to suffer from some form of neurological disorder.
  • These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors.
  • The 'Endocannabinoid System Targeted Therapeutics Market, 2020-2030' report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade.

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Retrieved on: 
Wednesday, July 22, 2020
Biotechnology, Health, Science, Other Science, Pharmaceutical, Branches of biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Molecular biology, Orexin, Hypocretin (orexin) receptor 2, Pyridines, Orexia, X-Chem

After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.

Key Points: 
  • After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.
  • Orexia will develop these molecules and is solely responsible for conducting clinical trials with drug candidates derived from licensed compounds, and retains the exclusive global rights to commercialize any resulting products.
  • The licensed compounds further strengthen Orexias promising pipeline of orexin positive modulators, said Mario Alberto Accardi, CEO of Orexia.
  • X-Chem subsequently used DEX screening data and its advanced informatics platform to identify small molecules for Orexia.

Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists

Retrieved on: 
Thursday, July 16, 2020
G protein-coupled receptors, Prostaglandin EP4 receptor

SAN DIEGO, July 16, 2020 /PRNewswire/ --Domain Associates and Catalys Pacific today announced the launch of Exalys Therapeutics Inc. with the closing of a $15 million Series A financing and the licensing of a platform of next-generation EP4 receptor antagonists from Eisai Co. Ltd. in Japan.

Key Points: 
  • SAN DIEGO, July 16, 2020 /PRNewswire/ --Domain Associates and Catalys Pacific today announced the launch of Exalys Therapeutics Inc. with the closing of a $15 million Series A financing and the licensing of a platform of next-generation EP4 receptor antagonists from Eisai Co. Ltd. in Japan.
  • "By selectively targeting EP4 to inhibit the immune response that leads to neuroinflammation after surgery, we believe our portfolio of novel EP4 antagonists can provide a safe and effective treatment for postoperative delirium.
  • Exalys' next-generation EP4 receptor antagonists have best-in-class properties for the treatment of EP4 driven indications.
  • Exalys Therapeutics is focused on developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with significant unmet need and limited treatment options.

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism

Retrieved on: 
Thursday, July 16, 2020
Branches of biology, Medical specialties, Organ systems, Anorectics, Peptides, Setmelanotide, G protein-coupled receptors, Proopiomelanocortin, Melanocortin 4 receptor, Obesity, Leptin, Bardet–Biedl syndrome

The Phase 2 study participants received a daily subcutaneous injection of setmelanotide.

Key Points: 
  • The Phase 2 study participants received a daily subcutaneous injection of setmelanotide.
  • We are encouraged by these Phase 2 study results and thank all the investigators for their efforts in conducting this important research.
  • The publication, Effect of Setmelanotide, an MC4R Agonist, on Obesity in Bardet-Biedl Syndrome, can be found online .
  • Rhythm submitted an MAA for setmelanotide to treat individuals living with POMC deficiency obesity or LEPR deficiency obesity to the EMA inJune 2020.

Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong

Retrieved on: 
Wednesday, July 8, 2020
Branches of biology, Molecular neuroscience, Neuropeptides, Neuroscience, Biology, Orexin, G protein-coupled receptors, RTT, Insomnia, Eisai

This application is the first application for DAYVIGO in Asia outside of Japan.

Key Points: 
  • This application is the first application for DAYVIGO in Asia outside of Japan.
  • Blocking the binding of wake-promoting neuropeptides orexin to orexin receptors is thought to balance sleep-wake circuitry by suppressing excessive wake drive.
  • (3),(4) In Hong Kong, over 35% of adults are reported to have symptoms of insomnia.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Endocannabinoid System Therapeutics Market, 2020-2030

Retrieved on: 
Thursday, June 18, 2020
Neurochemistry, Cannabinoids, G protein-coupled receptors, Endocannabinoid system

These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors.

Key Points: 
  • These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors.
  • The "Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade.
  • Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity for endocannabinoid system targeted therapeutics, over the next decade.

GLP-1 Receptor Agonist Market Size Worth $18.2 Billion By 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, June 10, 2020
G protein-coupled receptors, Peptide hormones, Anti-diabetic drugs, Diabetes, Glucagon-like peptide-1, Organ systems

SAN FRANCISCO, June 10, 2020 /PRNewswire/ -- The global GLP-1 receptor agonist market size is expected to reach USD 18.2 billion by 2027, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 10, 2020 /PRNewswire/ -- The global GLP-1 receptor agonist market size is expected to reach USD 18.2 billion by 2027, expanding at a CAGR of 6.1%, according to a new report by Grand View Research, Inc.
  • OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.
  • The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period.
  • Grand View Research has segmented the global GLP-1 receptor agonist market based on product and region:
    GLP-1 Receptor Agonist Product Outlook (Revenue, USD Million, 2016 - 2027)